Migraine Management in Saudi Arabia: Expert Consensus Including CGRP Drugs
Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of anti-CGRP therapies within the local healthcare context.
Quick Facts
What This Study Found
Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of anti-CGRP therapies within the local healthcare context.
Key Numbers
Expert consensus developed by Saudi neurologists reviewing international guidelines and local practice patterns.
How They Did This
Study design and methodology detailed in the full publication.
Why This Research Matters
These findings have significant implications for peptide-based therapeutic development and clinical practice.
The Bigger Picture
This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.
Questions This Raises
- ?What are the long-term implications?
- ?How do these results compare to existing evidence?
- ?What further research is needed?
Trust & Context
- Key Stat:
- Key finding Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of
- Evidence Grade:
- Evidence assessment based on study design detailed in publication.
- Study Age:
- Published in 2025. Current peptide therapeutic research.
- Original Title:
- Migraine management in Saudi Arabia: An expert consensus.
- Published In:
- Neurosciences (Riyadh, Saudi Arabia), 30(3), 169-176 (2025)
- Authors:
- Albilali, Abdulrazaq S, Alkawi, Ammar M, Alotaibi, Naser D, Qureshi, Shireen Am, Alabdali, Majed M, Alabdaly, Hani M, Alenzi, Bader A, Al Khathaami, Ali M, Elchami, Ziad M, Alesefir, Walid A
- Database ID:
- RPEP-09846
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this study mean for patients?
Expert consensus from Saudi Arabia provides migraine management guidelines including positioning of anti-CGRP therapies within the local healthcare context.
How reliable are these findings?
Evidence strength depends on study design. Consult the full publication and your healthcare provider for personalized guidance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09846APA
Albilali, Abdulrazaq S; Alkawi, Ammar M; Alotaibi, Naser D; Qureshi, Shireen Am; Alabdali, Majed M; Alabdaly, Hani M; Alenzi, Bader A; Al Khathaami, Ali M; Elchami, Ziad M; Alesefir, Walid A. (2025). Migraine management in Saudi Arabia: An expert consensus.. Neurosciences (Riyadh, Saudi Arabia), 30(3), 169-176. https://doi.org/10.17712/nsj.2025.3.20240118
MLA
Albilali, Abdulrazaq S, et al. "Migraine management in Saudi Arabia: An expert consensus.." Neurosciences (Riyadh, 2025. https://doi.org/10.17712/nsj.2025.3.20240118
RethinkPeptides
RethinkPeptides Research Database. "Migraine management in Saudi Arabia: An expert consensus." RPEP-09846. Retrieved from https://rethinkpeptides.com/research/albilali-2025-migraine-management-in-saudi
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.